COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Antidepressant Use During Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00279370
Recruitment Status : Completed
First Posted : January 19, 2006
Last Update Posted : October 7, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Katherine Wisner, University of Pittsburgh

Brief Summary:
This study will determine the safety of antidepressant use during pregnancy for both the mother and the child.

Condition or disease

Detailed Description:

Symptoms of major depressive disorder (MDD) include persistent sad mood, feelings of hopelessness or guilt, decreased energy, irritability, and more. If untreated, MDD can interfere with the ability to work, study, sleep, eat, and enjoy once pleasurable activities. MDD occurs most commonly in females between the ages of 25 and 44. This puts women of childbearing age at a particularly high risk for developing the disorder. However, very little research has been done to determine the safety of antidepressant use during pregnancy and how the medication may affect the baby. This study will determine the safety of antidepressant use during pregnancy for both the mother and the child.

Participants in this observational study will not receive medication or treatment of any kind. Pregnant woman who are already taking medication for depression will be recruited, in addition to pregnant women who are not taking any medication. The participants will first undergo interviews to establish their psychiatric diagnoses. Subsequent interviews will be held to monitor levels of depressive symptoms, exposure to other substances that could potentially harm the fetus, levels of antidepressants in the blood, and dietary intake during pregnancy. Participants will report to the study site for these evaluations at Weeks 20, 30, and 36 of pregnancy. From Week 36 to Week 40, interviews will be conducted over the phone.

At birth, cord blood will be collected and the infant's cries will be recorded. The infant's development will be assessed at 2 weeks and 3, 6 ½, 12, 18, and 24 months postpartum. Mothers who take selective serotonin reuptake inhibitors (SSRIs) and are breastfeeding their children will report to the study site with their children at 1 month postpartum to measure the level of SSRIs in the infant's blood. In addition, digital photographs of the infant's face, profile, hands, and torso will be taken at 2 weeks and 3, 12, and 24 months postpartum. Additional face-only photographs of the infant will be taken at these times and at birth for further in-depth analyses of facial characteristics. Mother-child interactions will be videotaped at all postpartum assessments.

Layout table for study information
Study Type : Observational
Actual Enrollment : 283 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Antidepressant Use During Pregnancy
Study Start Date : September 1999
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Primary Outcome Measures :
  1. SIGH-ADS [ Time Frame: 20, 30, 36 weeks gestation and 2, 12, 28, 52, and 104 weeks postpartum ]
  2. Bayley Scales of Infant Development [ Time Frame: 12, 28, 52, and 104 weeks postpartum ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women with or without active depression and with or without SSRI use in pregnancy

Inclusion Criteria:

  • Less than 24 weeks pregnant at the time of study entry
  • As of 12/1/2005, at significant risk for developing depression or currently taking SSRIs during pregnancy

Exclusion Criteria:

  • History of or current psychosis, bipolar disorder, or schizoaffective disorder
  • Current substance use disorder
  • Any medical condition that may be related to outcomes (such as multiple births or insulin-dependent diabetes)
  • Has not attended at least two prenatal visits at the 20-week intake point

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00279370

Layout table for location information
United States, Pennsylvania
Women's Behavioral HealthCARE Program
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Katherine L. Wisner, MD MS University of Pittsburgh, Department of Psychiatry
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Katherine Wisner, Professor of Psychiatry, Obstetrics and Gynecology and Reproductive Sciences, Epidemiology and Women's Studies, University of Pittsburgh Identifier: NCT00279370    
Other Study ID Numbers: R01MH060335 ( U.S. NIH Grant/Contract )
R01MH060335 ( U.S. NIH Grant/Contract )
First Posted: January 19, 2006    Key Record Dates
Last Update Posted: October 7, 2013
Last Verified: September 2013
Keywords provided by Katherine Wisner, University of Pittsburgh:
SSRI Exposure
Infant Development
Additional relevant MeSH terms:
Layout table for MeSH terms
Behavioral Symptoms